被忽视的群体:慢性肾脏病患者被排除于临床试验之外
本文指出慢性肾脏病患者,尤其是心血管临床试验中的患者,长期被排除在临床试验之外,导致其临床诊疗优化受阻。监管机构在促进CKD患者参与临床试验方面具有独特地位,患者协会和科学学会应积极游说监管机构,将此列为公共卫生优先事项。
要点
- CKD患者被排除在临床试验之外是长期未解决的问题
- 监管干预可有效改善特定人群的临床试验招募
- 患者协会和科学学会应推动监管机构重视此问题
核心结论
- 慢性肾脏病患者被排除在临床试验之外的问题长期存在且未解决,阻碍了其临床诊疗优化。
主要发现
- CKD患者,尤其是心血管临床试验中的患者,被排除在临床试验之外。
- 女性在心血管试验中招募不足的问题通过监管干预得以解决,可作为参照。
临床怎么用
- 监管机构应促进CKD患者参与临床试验。
- 患者协会和科学学会应游说监管机构将此事列为公共卫生优先事项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The exclusion of chronic kidney disease (CKD) patients from clinical trials-particularly cardiovascular trials-remains a long-standing, unsolved problem, which prevents the optimization of clinical care in these patients. The situation recalls the insufficient recruitment of women in cardiovascular trials until the 1980s, a problem that was only resolved following regulatory interventions. Regulatory agencies are in a unique position to promote recruitment of CKD patients in clinical trials. The main stakeholders, namely patients' associations and scientific societies, should make major lobbying efforts to persuade these agencies that the issue is an absolute public health priority.
引用
- Zoccali C, Blankestijn PJ, Bruchfeld A, et al. Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials. Nephrol Dial Transplant. 2019. PMID: 30815678. doi:10.1093/ndt/gfz023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。